Skip to main content

Jasper Therapeutics, Inc.

JSPR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001788028

No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.

Other share classesJSPRW

Q3 2025 vs. Q2 2025

How the institutions holding Jasper Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of JSPR: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders6560−5
Shares12.5M20.2M+7.64M (+61.1%)
Value$69.5M$47.8M−$21.6M (−31.2%)

New holders (15)

Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to JSPR in Q3 2025
InstitutionSharesValue% of portfolio
Acorn Capital Advisors, LLC1,382,640$3.29M1.67%
Woodline Partners LP1,039,751$2.47M0.01%
Propel Bio Management, LLC1,028,806$2.45M2.45%
Simplify Asset Management Inc.609,053$1.45M0.03%
Boothbay Fund Management, LLC442,642$1.05M0.03%
Armistice Capital, LLC348,000$828.2K0.03%
Knott David M Jr171,389$407.9K0.17%
Readystate Asset Management LP98,439$234.3K0.01%
Ieq Capital, LLC48,118$114.5K0.00%
Two Sigma Investments, LP40,427$96.2K0.00%
Voleon Capital Management LP20,950$49.9K0.00%
Stonepine Capital Management, LLC20,200$48.1K0.04%
Group One Trading, L.P.17,550$41.8K0.00%
Jones Financial Companies LLLP50$1240.00%
Optiver Holding B.V.6$140.00%

Sold out (20)

Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.